These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34505407)

  • 1. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
    Giovannelli J; Ciron J; Cohen M; Kim HJ; Kim SH; Stellmann JP; Kleiter I; McCreary M; Greenberg BM; Deschamps R; Audoin B; Maillart E; Papeix C; Collongues N; Bourre B; Laplaud D; Ayrignac X; Durand-Dubief F; Ruet A; Vukusic S; Marignier R; Dauchet L; Zephir H;
    Ann Clin Transl Neurol; 2021 Oct; 8(10):2025-2037. PubMed ID: 34505407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
    Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
    Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
    J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
    J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
    Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.
    Huang W; Wang L; Zhang B; Zhou L; Zhang T; Quan C
    Mult Scler Relat Disord; 2019 Oct; 35():246-252. PubMed ID: 31425902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.
    Magdalena C; Clarissa A; Sutandi N
    Innov Clin Neurosci; 2022; 19(4-6):51-64. PubMed ID: 35958974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.